Press Releases

Dr. Keefe to lead the product development and manufacturing of BlueSphere Bio’s first clinical candidate, a TCR T-cell therapy directed against the miHA HA-1. PITTSBURGH, PA, April 26, 2022 — BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and […]

TCXpress™ identified a diverse set of novel T-cell receptors (TCRs) with in vitro reactivity against the minor histocompatibility antigen HA-1, from a single donor Data support the broad potential of TCXpress™ to rapidly and efficiently identify TCRs with activity against a selected target PITTSBURGH, PA, April 8, 2022 — BlueSphere Bio, a T-cell receptor (TCR)

PITTSBURGH, PA, March 15, 2022 — BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a revolutionary TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced that Sawa Ito, M.D., Ph.D., hematologist/oncologist at UPMC Hillman Cancer Center and Assistant Professor, Division of Hematology-Oncology and of Immunology

PITTSBURGH, PA, February 8, 2022 — BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a revolutionary TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced that David Apelian, M.D., Ph.D., MBA, chief executive officer of BlueSphere Bio, will present an in-person company overview at the

Today BlueSphere Bio announces the appointment of Jonathan Peacock as Chairman of the Board of Directors in its pursuit to build an industry leading Board and executive team to develop their groundbreaking immune oncology T cell receptor (TCR) T-cell discovery platform and clinical programs. Mr. Peacock brings a wealth of experience from the biotech and

Immuno-oncology startup BlueSphere Bio, a company developing its novel T cell receptor search and capture platform, TCXpress, to create rapid personalized T cell therapies for cancer and blood and marrow transplantation, has named immunotherapy pioneer Alan Korman, Ph.D., to its board of directors. Korman brings more than three decades of immunotherapy and biotechnology experience to

BlueSphere Bio, which was established by UPMC Enterprises, uses its novel TCXpress platform to obtain and characterize T cell receptors, the key component for any T cell immunotherapy. This technology, developed at the University of Pittsburgh, is an efficient, cost-effective alternative to conventional methods of using a person’s own T cells to create individualized treatments.

BlueSphere Bio, an immunotherapy startup focused on creating personalized T cell therapies for cancer, today announced the members of its newly formed scientific advisory board. Composed of internationally renowned scientists with deep expertise that spans basic T cell immunology to cutting edge adoptive T cell immunotherapies, the board will provide vital guidance for BlueSphere Bio

BlueSphere Bio, an immunotherapy startup formed by UPMC Enterprises and focused on creating personalized therapies for cancer, announced today that David Apelian, M.D., Ph.D., M.B.A., has been named chief executive officer of the company. He joins top clinical immunology experts and company co-founders Mark Shlomchik, M.D., Ph.D., and Warren Shlomchik, M.D., of the University of